• Je něco špatně v tomto záznamu ?

Mirabegron improves quality-of-life, treatment satisfaction, and persistence in patients with overactive bladder: a multi-center, non-interventional, real-world, 12-month study

R. Freeman, S. Foley, J. Rosa Arias, E. Vicente, R. Grill, Z. Kachlirova, A. Stari, M. Huang, N. Choudhury,

. 2018 ; 34 (5) : 785-793. [pub] 20180110

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19035471

OBJECTIVE: Observational studies can provide evidence about patient outcomes in routine clinical practice. This prospective, non-interventional study (BELIEVE) is the largest real-world European study to date to assess quality-of-life, treatment satisfaction, resource utilization, and persistence in patients with overactive bladder (OAB) who were prescribed mirabegron as part of routine clinical practice. METHODS: The primary objective was to evaluate change from baseline in quality-of-life based on overactive bladder questionnaire (OAB-q) sub-scales. Secondary objectives included evaluation of treatment persistence, patient satisfaction, healthcare resource utilization and adverse events (AEs). Follow-up was for 12 months with visit windows at 2-4 and 10-12 months. Median change from baseline in total OAB-q and its sub-scales (Health-related quality-of-life [HRQoL] and symptom bother scale) were assessed. RESULTS: Overall, 862 patients were enrolled from eight European countries. In the Full Analysis Set (FAS), 73.7% were female, mean age was 61.2 years; 47.7% ≥65 years. At baseline, 41.3% had switched from other OAB treatments, 42.2% were treatment naïve, 10.1% were lapsed, and 6.4% were on combination treatment. Symptom bother and HRQoL total scores improved from baseline to 2-4 and 10-12 months. There was a notable improvement in dry rate, increasing from 34.9% at baseline to 43.7% at 10-12 months in the FAS, and a reduction in pad use. Persistence was high, with 53.8% of FAS patients remaining on mirabegron at 10-12 months. Overall, no unexpected safety issues were observed and AEs were consistent with the known safety profile of mirabegron. CONCLUSION: Patients receiving mirabegron in a real-world setting reported meaningful improvements in QoL and health status, with a persistence rate of 53.8% at 12 months for the FAS. No unexpected safety issues were observed, and AEs were consistent with the known safety profile of mirabegron.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19035471
003      
CZ-PrNML
005      
20191014092046.0
007      
ta
008      
191007s2018 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1080/03007995.2017.1419170 $2 doi
035    __
$a (PubMed)29254376
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Freeman, Robert $u a Derriford Hospital , Plymouth , Devon , UK.
245    10
$a Mirabegron improves quality-of-life, treatment satisfaction, and persistence in patients with overactive bladder: a multi-center, non-interventional, real-world, 12-month study / $c R. Freeman, S. Foley, J. Rosa Arias, E. Vicente, R. Grill, Z. Kachlirova, A. Stari, M. Huang, N. Choudhury,
520    9_
$a OBJECTIVE: Observational studies can provide evidence about patient outcomes in routine clinical practice. This prospective, non-interventional study (BELIEVE) is the largest real-world European study to date to assess quality-of-life, treatment satisfaction, resource utilization, and persistence in patients with overactive bladder (OAB) who were prescribed mirabegron as part of routine clinical practice. METHODS: The primary objective was to evaluate change from baseline in quality-of-life based on overactive bladder questionnaire (OAB-q) sub-scales. Secondary objectives included evaluation of treatment persistence, patient satisfaction, healthcare resource utilization and adverse events (AEs). Follow-up was for 12 months with visit windows at 2-4 and 10-12 months. Median change from baseline in total OAB-q and its sub-scales (Health-related quality-of-life [HRQoL] and symptom bother scale) were assessed. RESULTS: Overall, 862 patients were enrolled from eight European countries. In the Full Analysis Set (FAS), 73.7% were female, mean age was 61.2 years; 47.7% ≥65 years. At baseline, 41.3% had switched from other OAB treatments, 42.2% were treatment naïve, 10.1% were lapsed, and 6.4% were on combination treatment. Symptom bother and HRQoL total scores improved from baseline to 2-4 and 10-12 months. There was a notable improvement in dry rate, increasing from 34.9% at baseline to 43.7% at 10-12 months in the FAS, and a reduction in pad use. Persistence was high, with 53.8% of FAS patients remaining on mirabegron at 10-12 months. Overall, no unexpected safety issues were observed and AEs were consistent with the known safety profile of mirabegron. CONCLUSION: Patients receiving mirabegron in a real-world setting reported meaningful improvements in QoL and health status, with a persistence rate of 53.8% at 12 months for the FAS. No unexpected safety issues were observed, and AEs were consistent with the known safety profile of mirabegron.
650    _2
$a acetanilidy $x terapeutické užití $7 D000083
650    _2
$a senioři $7 D000368
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a spokojenost pacientů $x statistika a číselné údaje $7 D017060
650    _2
$a prospektivní studie $7 D011446
650    12
$a kvalita života $7 D011788
650    _2
$a průzkumy a dotazníky $7 D011795
650    _2
$a thiazoly $x terapeutické užití $7 D013844
650    12
$a hyperaktivní močový měchýř $x farmakoterapie $x epidemiologie $x psychologie $7 D053201
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Foley, Steve $u b Royal Berkshire Hospital , Reading , Berkshire UK.
700    1_
$a Rosa Arias, José $u c Department of Urology , Hospital Comarcal Santiago Apóstol , Miranda de Ebro-Burgos , Spain.
700    1_
$a Vicente, Eduardo $u d Urology Department , Parc Taulí University Hospital , Sabadell, Barcelona , Spain.
700    1_
$a Grill, Robert $u e Charles University , Prague , Czech Republic.
700    1_
$a Kachlirova, Zuzana $u e Charles University , Prague , Czech Republic.
700    1_
$a Stari, Anny $u f Astellas Pharma Europe Ltd , Chertsey , Surrey UK.
700    1_
$a Huang, Moses $u f Astellas Pharma Europe Ltd , Chertsey , Surrey UK.
700    1_
$a Choudhury, Nurul $u f Astellas Pharma Europe Ltd , Chertsey , Surrey UK.
773    0_
$w MED00009520 $t Current medical research and opinion $x 1473-4877 $g Roč. 34, č. 5 (2018), s. 785-793
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29254376 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20191014092510 $b ABA008
999    __
$a ok $b bmc $g 1452131 $s 1074021
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 34 $c 5 $d 785-793 $e 20180110 $i 1473-4877 $m Current medical research and opinion $n Curr Med Res Opin $x MED00009520
LZP    __
$a Pubmed-20191007

Najít záznam

Citační ukazatele

Možnosti archivace